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Summary Eighty-one patients with small cell lung cancer (SCLC) with a survival of more than 2 years after
start of chemotherapy were studied. Twenty-six of the 28 patients who died of relapsed SCLC had in fact
relapsed before two years and of the 55 who had not then only two (4%) relapsed subsequently. It is stressed
that with such observations treatment related factors should be taken in account. Second tumours were
observed in ten patients, nine proven malignant. Of the eight patients with non-small cell lung cancer three
had residual disease after initial chemotherapy. In our patient group after a 2 year disease-free interval the risk
of developing non-small cell lung cancer seems higher than a subsequent relapse of SCLC.
In recent years a number of studies have been published
concerning prognostic factors of patients with small-cell lung
cancer (SCLC). Most patients who achieve long-term survival
after treatment for SCLC initially present with favourable
prognostic factors such as good performance status, limited
disease, female gender, few biochemical abnormalities and
good response to treatment (Albain et al., 1990; Osterlind &
Anderson, 1986; Spiegelman et al., 1989). However when
these patients have reached a survival of more than 2 or 3
years after start of treatment such factors have lost their
predictive value for further disease-free survival or subse-
quent relapse.
A number of studies have focused solely on those patients
who achieve long-term survival (Davis et al., 1985; Niiranen,
1988; Jackson et al., 1988; Pallares et al., 1987; Souhami &
Law, 1990). In order to gather more knowledge about the
fate of patients with SCLC who obtain long-term survival we
performed a retrospective study of all consecutively treated
patients in four different centres with a survival of more than
24 months after start of treatment. Special attention was paid
to subsequent relapse and the development of secondary
malignancies. No attempt was made to study the differences
in pretreatment prognostic factors between this group of
patients and the parent group since these factors are well
known from the literature.
Patients and methods
The medical records of all patients with SCLC defined ac-
cording to the morphological criteria of the WHO (1982) and
diagnosed between 1980 and 1989 in four different centres
were reviewed. Eighty-one patients were identified who sur-
vived more than 2 years after start of chemotherapy.
Minimal staging procedures for almost all patients had
included physical examination, chest X-ray, computed
tomography scan or ultrasound of the upper abdomen, bone
scan and unilateral bone-marrow biopsy. Limited disease
(LD) was defined as disease confined to one hemithorax
including ipsilateral hilar, mediastinal lymph nodes, and sup-
raclavicular lymph nodes and extensive disease (ED) as
disease spread beyond the hemithorax including extension to
the chest wall or to the contralateral lung. In 52 patients the
initial chemotherapy regimen consisted of doxorubicin,
cyclocphosphamide, and etoposide. Ten patients were treated
with the combination of cisplatin, cyclophosphamide and
etoposide. Eight patients were treated with a combination
consisting of cyclphosphamide, vincristine and procarbazine
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in four patients combined with CCNU. Four patients were
treated with the combination of cisplatin, doxorubicin and
etoposide and three with a combination of cyclophos-
phamide, vincristine and etoposide. Two patients were
treated with carboplatin and ifosfamide and one patient with
carboplatin and vincristine. Another patient received a com-
bination of cyclophosphamide, methotrexate and CCNU.
Nine of these patients received chemotherapy after surgical
resection of the tumour.
Tumour response was evaluated by standard WHO criteria
(1979). Survival was recorded from the start of treatment to
death or last follow-up. Survival curves were calculated ac-
cording to the method of Kaplan-Meier. Additional clinical
characteristics are shown in Table I.
Results
The overall survival curve of the patients from 2 years after
start of chemotherapy is shown in Figure 1. At the time of
analysis 43 patients had died with a median survival of 143
weeks (range 106-464). The causes of death are listed in
Table II. The causes of death were available from the hos-
pital records for most patients. In some instances further
information was obtained from the patients general physician
to obtain additional information about the cause of death.
Twenty-eight patients died from progressive SCLC.
Twenty-one, five and two patients died in the third, fourth
and fifth year respectively. The survival curve in Figure 2
shows the death from SCLC censored for non-SCLC deaths.
Twenty-six of these 28 patients had already evidence of
disease progression before they had reached a survival 2
years after start of treatment. More than 60% of the
twenty-three patients treated with reinduction chemotherapy
achieved an objective response to second-line treatment. The
two patients who had no evidence of disease 24 months after
Table I Patient characteristics
No. patients 81
Median age (years) 60 (range 35-74)
Sex
male 65 (80%)
female 16 (20%)
Median performance status (Karnofsky) 90% (range 30-100)
Limited disease 68 (84%)
Extensive disease 13 (16%)
Response
complete response 65 (80%)
partial response 6 (7%)
stable disease 1 (1%)
non-evaluable (adjuvant chemotherapy) 9 (II%)
Chest irradiation 33 (41%)
Prophylactic cranial irradiation 60 (74%)
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Figure 2 Survival curve of 81 patients with small cell lung cancer with a survival of more than 2 years after start of treatment.
Table II Causes of death
No. ofpatients
Recurrent SCLC 28
Second malignancies 9
Non small cell lung cancer 8
Non-Hodgkin lymphoma 1
Recurrent pulmonary tumour (no histology) I
Non-malignant causes 3
Unknown 2
start of chemotherapy relapsed 30 and 50 months after start
of treatment, one with liver and bone metastases and the
other with brain metastases.
Second tumours were observed in ten patients, nine proven
malignant. Of the eight patients with non-small cell lung
cancer three had residual disease after initial chemotherapy
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which proved tobe non-small lung cancer (one adenocar-
cinoma and two squamous cell carcinoma). It seems probable
that these three patients had tumours with a mixed histology
at presentation. The other five patients developed non-small
cell lung cancer 19, 47, 56, 60 and 84 months after diagnosis
of SCLC. All these five patients had a histological diagnosis
of squamous cell carcinoma. Although five of these patients
were operated and three were treated with radiotherapy all
eight patients died due to distant metastases of non-small cell
lung cancer. One patient developed and died due to a non-
Hodgkin lymphoma of the small intestines at 7 years. The
chemotherapy regimen of this patients had included a com-
bination of cyclophosphamide, vincristine and procarbazine
which might have attributed to the development of this non-
Hodgkin lymphoma. One patient died due to a recurrent
pulmonary tumour 7 years after diagnosis of SCLC but no
histological diagnosis could be obtained.
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Figure 2 Death from small cell lung cancer alone, death from non-small cell lung cancer censored.
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Non-malignant causes of death were found in three
patients. In two patients the cause of death was unknown. Of
the nine patients who received chemotherapy after surgical
resection of the tumour, five patients are still alive without
recurrent disease and a median survival of 70 months (range
52-120).
Of the 13 patients with extensive disease all patients had
metastases to only one organ site. Four of these patients
have still no evidence of disease with a follow-up of 65, 69,
72 and 80 months after start ofchemotherapy. There was not
a significant difference between the survival curves of the
patients who were initially staged as limited or extensive
disease beyond a survival of more than 2 years.
Discussion
Although SCLC is a chemosensitive disease the number of
patients surviving for more than 2 years is still low and
relapses as late as 8 years after diagnosis have been reported
(Vogelsang et al., 1985). As can be seen in Table I most of
the patients who achieved long-term survival presented with
initial favourable prognostic factors and most patients had
few biochemical abnormalities.
Of the 81 patients with a survival of more than 24 months
after start of treatment 35% died from progressive SCLC up
till 55 months. The overall survival curve is quite similar to
those reported by Souhami & Law (1990). Remarkably only
two of the 55 patients (4%) with a disease-free survival of
more than 2 years have relapsed after a median follow-up of
5.7 years. Osterlind et al. (1986) reported on 72 patients
disease-free at restaging 18 months after start of treatment.
During the first 6 months after restaging 19 patients relapsed
and 14 of 53 patients (26%) relapsed after a disease-free
interval of more than 24 months with a minimum follow-up
of 4 years. One explanation for this observed difference in
relapse rates may be that in contrast to the Danish study
75% of our patients did not receive chemotherapy for a
duration of more than 6 months. Although maintenance
treatment has probably no impact on overall survival it
seems to increase the disease-free interval (Spiro et al., 1989;
Splinter, 1988). Therefore patients who have received
chemotherapy for 18 months and who are still disease-free at
two years have a higher relapse rate than patients who have
received chemotherapy for a shorter period. The favourable
survival of some of the patients who had already relapsed
before they had reached a survival for more than 2 years and
the high response to reinduction chemotherapy also argues
for this hypothesis (Postmus et al., 1987).
Lung tumours with a non-small cell histology were
encountered in eight patients. In three patients the non-small
cell histology became apparent in the residual tumour after
they had been given treatment for SCLC. Five patients were
diagnosed with non-small cell carcinoma of the lung 19-84
months after the diagnosis of SCLC. Johnson et al. (1986)
estimated the risk of development of non-small cell lung
carcinoma after two years of disease-free survival 4.4% per
person year. Since in our study 55 patients were disease-free
at 24 months with a median follow-up of 5.7 years the
expected number of patients who had developed non-small
cell lung cancer would have been 8 patients. Despite the fact
that all of these patients had been followed on a regular basis
and therefore theoretically these tumours should have been
detected at a rather early stage and furthermore at least five
patients had operable disease at presentation, all these
patients died due to distant metastases. Data about the prog-
nosis of patients who develop a second primary lung car-
cinoma after small cell carcinoma are scarce. Craig et al.
(1984) reported on ten patients of whom the survival after
diagnosis of the second primary was greater than 6 months
in only one patient. In the earlier mentioned study of John-
son no patient survived more than 40 weeks from histologic
documentation of the second cancer (Johnson et al., 1986).
Until now there is no obvious explanation for the dismal
prognosis of these patients.
In conclusion we observed in this study a low relapse rate
(4%) of SCLC after a disease-free interval of more than 2
years. It is stressed that with such observations treatment
related factors should be taken in account. Since after a 2
year disease-free interval the risk of developing NSCLC
seems higher than a subsequent relapse of SCLC follow-up
should be focused on early detection of a second primary.
More data are required to show whether the prognosis of
those patients who develop a second primary NSCLC is
worse than those patients who develop a second primary
NSCLC than of patients who develop NSCLC without
antecedent SCLC and whether or not chemo-prevention trials
in such a high risk group may be worthwhile.
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